Senseonics Holdings Inc (NASDAQ:SENS), the developer of long-term implantable continuous glucose monitoring (CGM) systems, reported its fourth quarter and full-year 2025 financial results after the market close on March 2, 2026. The report presented a mixed picture of accelerating revenue growth against a backdrop of significant ongoing investments and losses, leading to a negative reaction in after-hours trading.
Earnings and Revenue Versus Estimates
The company's headline revenue figure showed robust year-over-year growth but came in slightly below Wall Street's expectations for the quarter. Meanwhile, the net loss per share was wider than analysts had anticipated.
- Q4 2025 Revenue: Reported at $14.3 million, a substantial 72% increase from $8.3 million in Q4 2024.
- Analyst Revenue Estimate: The consensus estimate was for $14.62 million. Senseonics' result represents a slight miss of approximately 2.2%.
- Q4 2025 EPS (Non-GAAP): Reported a loss of ($0.46) per share.
- Analyst EPS Estimate: The consensus expected a loss of ($0.443) per share.
For the full year 2025, the company generated total revenue of $35.3 million, a 57% increase over the prior year. The annual net loss improved to $69.1 million ($1.66 per share) from $78.6 million ($2.50 per share) in 2024, driven by a significant improvement in gross profit margin.
Market Reaction and Price Action
Following the earnings release, shares of Senseonics traded lower in the after-hours session, declining approximately 3.2%. This immediate reaction suggests investor focus on the twin misses on revenue and earnings per share, overshadowing the strong percentage growth rates. The stock had shown positive momentum in the lead-up to the report, gaining roughly 13.6% over the past month, indicating some bullish anticipation that the results may not have fully met.
Key Highlights from the Earnings Report
Beyond the quarterly figures, management highlighted several strategic accomplishments and provided forward-looking guidance:
- Commercial Transition: The company successfully executed agreements to bring the commercialization and distribution of its Eversense systems fully in-house from former partner Ascensia Diabetes Care, effective January 1, 2026.
- Strong U.S. Growth: U.S. revenue more than doubled in Q4, driven by a 103% year-over-year increase in new patient growth, attributed to direct-to-consumer marketing efforts.
- Pipeline and Regulatory Progress: Received CE Mark approval for the Eversense 365 system in Europe and launched its first Automated Insulin Delivery (AID) system integration with the twiist system in the U.S. The company also enrolled the first patients in the pivotal trial for its next-generation, self-powered Gemini sensor.
- Increased Operating Expenses: Selling, general, and administrative expenses rose sharply to $19.8 million in Q4 (from $8.9 million a year ago) due to investments in the commercial infrastructure, marketing, and costs associated with the Ascensia transition.
2026 Financial Outlook and Analyst Comparison
Management provided specific revenue and margin guidance for the full year 2026, which appears ambitious compared to current analyst sales estimates.
- Company's 2026 Revenue Guidance: Senseonics expects full-year 2026 global net revenue between $58 million and $62 million. This represents projected growth of 65% to 76% over 2025.
- Analyst 2026 Sales Estimate: The current consensus sales estimate for 2026 stands at approximately $60.64 million, which sits near the midpoint of the company's provided range.
- Gross Margin Guidance: The company anticipates gross margins of approximately 50% for the full year 2026, a significant improvement from 2025.
For the upcoming first quarter of 2026, analyst estimates project sales of about $9.48 million and an EPS loss of ($0.57). Senseonics did not provide specific Q1 guidance.
Conclusion
Senseonics' Q4 2025 results underscore a company in a critical investment phase. While top-line growth is accelerating impressively as it takes control of its commercial destiny, the costs of building that independent sales and marketing engine are substantial and are pressuring the bottom line in the near term. The after-hours stock decline reflects the market's immediate judgment on the earnings and revenue misses. The primary focus for investors now shifts to the company's ability to execute on its aggressive 2026 revenue guidance and achieve the promised scale and profitability improvements as its commercial strategy unfolds in the U.S. and Europe.
For a detailed look at future quarterly estimates and historical earnings performance, you can review the earnings and estimates data for Senseonics here.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial analysis, or a recommendation to buy, sell, or hold any security. The data presented is based on publicly available information and analyst estimates, which are subject to change. Readers should conduct their own research and consult with a qualified financial advisor before making any investment decisions.
